tiprankstipranks
Advertisement
Advertisement

TRDA Stock Latest News

Entrada Therapeutics Stockholders Approve Directors and Equity Plans
Company AnnouncementsEntrada Therapeutics Stockholders Approve Directors and Equity Plans
7d ago
8K
TRDA
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
PremiumThe Fly
Entrada Therapeutics price target lowered to $17 from $20 at Guggenheim
9d ago
TRDA
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
PremiumCompany Announcements
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress
29d ago
8K
TRDA
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
PremiumThe Fly
Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital
1M ago
NVS
TRDA
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
1M ago
TRDA
Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
PremiumThe FlyEntrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study
1M ago
TRDA
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
Premium
Ratings
Buy Rating Reaffirmed on TRDA as ENTR‑601‑44 Shows Clinically Meaningful Functional Gains and Higher-Dose Data Loom as Key Catalyst
1M ago
TRDA
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
Premium
The Fly
Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)
1M ago
TRDA
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
PremiumCompany Announcements
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data
1M ago
8K
TRDA
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
PremiumThe Fly
Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer
2M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
TRDA
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
PremiumThe Fly
Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald
3M ago
TRDA
Entrada Therapeutics management to meet with Oppenheimer
PremiumThe FlyEntrada Therapeutics management to meet with Oppenheimer
3M ago
TRDA
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
Premium
Ratings
Advancing Exon-Skipping and Undervalued DM1 Collaboration Underscore Buy Rating on Entrada Therapeutics
4M ago
TRDA
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
Premium
The Fly
Entrada Therapeutics price target raised to $19 from $13 at Roth Capital
4M ago
TRDA
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
PremiumThe Fly
Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)
4M ago
TRDA
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
PremiumRatings
Advancing DMD and DM1 Pipeline Positions Entrada for Multiple Near‑Term Catalysts and Upside Potential
4M ago
TRDA
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
PremiumRatings
Entrada Therapeutics: Advancing ENTR-601-44 Positions Platform for Best-in-Class Dystrophin Restoration and Attractive Risk/Reward
4M ago
TRDA
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
PremiumThe Fly
Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study
4M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
PremiumThe FlyEntrada Therapeutics initiated with a Buy at Guggenheim
4M ago
TRDA
Entrada Therapeutics initiated with a Buy at Guggenheim
Premium
The Fly
Entrada Therapeutics initiated with a Buy at Guggenheim
4M ago
TRDA
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Premium
The Fly
Entrada Therapeutics initiated with an Outperform at Oppenheimer
5M ago
TRDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >